MIM
JAZZ icon

Macroview Investment Management’s Jazz Pharmaceuticals JAZZ Stock Holding History

Macroview Investment Management’s Portfolio JAZZ Stock Details JAZZ Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2020
Q4 		– Sell
-18
Closed -$3K – 360
2020
Q3 		$3K Buy
+18
New +$2.23K 0.01% 216
2020
Q2 		– Sell
-23
Closed -$2K – 351
2020
Q1 		$2K Sell
23
-2
-8% -$259 ﹤0.01% 232
2019
Q4 		$4K Buy
+25
New +$3.4K 0.01% 193

Other funds holding JAZZ

BlackRock
BlackRock New York $6.73T AUM 46.02% 1-Year Est. Return
Vanguard Group
Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return
Renaissance Technologies
Renaissance Technologies New York $72.6B AUM 54.88% 1-Year Est. Return
Fidelity Investments
Fidelity Investments Boston, Massachusetts $2.3T AUM 54.33% 1-Year Est. Return
LSV Asset Management
LSV Asset Management Chicago, Illinois $55.1B AUM 45.38% 1-Year Est. Return
State Street
State Street Boston, Massachusetts $3.38T AUM 44.17% 1-Year Est. Return
JP Morgan Chase
JP Morgan Chase New York $1.81T AUM 41.13% 1-Year Est. Return
AQR Capital Management
AQR Capital Management Greenwich, Connecticut $287B AUM 42.33% 1-Year Est. Return
Boston Partners
Boston Partners Boston, Massachusetts $113B AUM 38.87% 1-Year Est. Return
Citadel Advisors
Citadel Advisors Miami, Florida $875B AUM 40.89% 1-Year Est. Return

Macroview Investment Management's JAZZ Position: Q4 2020 in Review

Macroview Investment Management sold out of Jazz Pharmaceuticals (JAZZ) in Q4 2020, closing a stake of 18 shares — an estimated $3K sold.

Macroview Investment Management first reported a position in JAZZ in Q4 2019 and held it in 3 quarters. The position peaked at $4K in Q4 2019. 437 funds tracked by Wall St. Rank hold JAZZ as of Q4 2020.

  • Macroview Investment Management reported no remaining Jazz Pharmaceuticals position as of Q4 2020 after selling out during the quarter.
  • Macroview Investment Management sold 18 Jazz Pharmaceuticals shares in Q4 2020, an estimated $3K.
  • Macroview Investment Management first reported a position in Jazz Pharmaceuticals in Q4 2019 and held it in 3 quarters.
  • Macroview Investment Management's Jazz Pharmaceuticals position peaked at $4K in Q4 2019.
  • 437 funds tracked by Wall St. Rank held Jazz Pharmaceuticals as of Q4 2020.

Based on Macroview Investment Management's 13F filing for Q4 2020, filed 29 Jan 2021.